Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference

SOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST ), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Tom Dubensky, Ph.D., will participate in a panel titled "Developing Therapies for the Next Immuno-Oncology Targets" at the 2022 William Blair Biotech Focus Conference on Tuesday, July 12, 2022 at 4:10 p.m. ... Full story available on Benzinga.com